RxDoctor Payments Data

David Montgomery, MD

Cardiovascular Disease · Sandy Springs, GANPI 1407027014

Payments from drug & device makers

$9,398in general payments, 2019–2025

Across 169 payments — averaging $55.61 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Amarin Pharma, Inc.$7K
  • Amgen$432
  • Johnson & Johnson$389
  • Novartis$320
  • Arbor Pharmaceuticals, Inc.$266
  • Esperion Therapeutics, Inc.$206
  • plus $814 from 18 others

What the payments were for

  • Speaking & faculty fees$5,04054%
  • Travel & lodging$7768%
  • Food & beverage$3,56438%
  • Education$180%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$9,398 in reported general payments places this provider in the 80th percentile of 640 cardiovascular disease providers in Georgia.

See all cardiovascular disease providers in Georgia

Medicare billing

Part B allowed, 2024
$212,058
Medicare patients
464
Services billed
2,156

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
XareltoRivaroxaban96$125,563
EliquisApixaban71$95,831
JardianceEmpagliflozin37$42,460
Repatha SureclickEvolocumab28$38,902
NexlizetBempedoic Acid/Ezetimibe32$30,682
Repatha PushtronexEvolocumab18$17,612
Olmesartan-Amlodipine-HctzOlmesartan/Amlodipin/Hcthiazid99$11,412
OzempicSemaglutide11$9,671
LivaloPitavastatin Calcium25$9,229
EdarbyclorAzilsartan Med/Chlorthalidone27$8,614
EdarbiAzilsartan Medoxomil14$7,383
Bisoprolol Fumarate201$6,455
Olmesartan-HydrochlorothiazideOlmesartan/Hydrochlorothiazide142$5,779
Isosorbide Dinit-HydralazineIsosorbide Dinit/Hydralazine13$4,163
Atorvastatin Calcium380$3,750

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Johnson & JohnsonXarelto$389$125,56396 claims
PfizerEliquis$61$95,83171 claims
Boehringer IngelheimJardiance$84$42,46037 claims
Esperion Therapeutics, Inc.Nexlizet$206$30,68232 claims
Arbor Pharmaceuticals, Inc.Edarbyclor, Edarbi$266$15,99741 claims
Novo NordiskOzempic$89$9,67111 claims
Kowa Pharmaceuticals America, Inc.Livalo$33$9,22925 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 640 cardiovascular disease providers in Georgia.

Other cardiovascular disease in Sandy Springs

See the full list for Georgia

Where these figures come from

Is this you, or does something look wrong? →